Search

Could cell-based synthetic circuits make pills and ointments a thing of the past for chronic disease?

Michela Gallagher was studying aging in lab rats when an unusual finding launched her on a translational journey that now sees her poised to initiate a Phase III trial of a drug to delay the onset of Alzheimer’s dementia.

As a neurologist, Bradley Hyman has seen first-hand the impact of Alzheimer’s disease on patients and their families.

Our understanding of the mechanisms that trigger Alzheimer’s disease is growing fast, but many secrets still lurk in the shadowy recesses of the brain.

Better understanding of human biology presents us with an opportunity to combat disease on two fronts – targeting individual variation on one hand and universal mechanisms on the other.

Holding back the “guardian of the genome” opens the gates to more efficient transdifferentiation

A galaxy-mapping statistical model suggests that star-shaped astrocytes are repelled by Alzheimer’s plaques

Telling stories from across the translational spectrum